Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083333 | 1.00 | CYP19A1 (0.42) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL8083271 | 0.92 | CYP19A1 (0.42) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL8083273 | 0.86 | CYP19A1 (0.38) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL7022136 | 0.85 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL8083240 | 0.81 | CYP19A1 (0.49) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL6849024 | 0.80 | CYP19A1 (0.40) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL7027408 | 0.80 | CYP19A1 (0.55) | CYP19A1AR | |
| SCHEMBL3660111 | 0.77 | CYP19A1 (0.55) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL7030182 | 0.76 | CYP19A1 (0.49) | CYP19A1AR | |
| SCHEMBL9626851 | 0.76 | CYP19A1 (0.49) | CYP19A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |